Cellid Co. Ltd (299660.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7299660001
Cellid Co. Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.17 bn KRW | 8.84 bn KRW |
| Gross profit | 705.01 m KRW | 1.58 bn KRW |
| Operating income | -11.79 bn KRW | -11.34 bn KRW |
| EBIT | -11.79 bn KRW | -11.93 bn KRW |
| Net income | -12.26 bn KRW | -12.07 bn KRW |
| Diluted EPS – continuing operations | -515.96 KRW | -409.08 KRW |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
More stocks
- Organto Foods Incorporated (OGO.V)
- EXOZYMES INC. (EXOZ)
- Sino Green Land Corp. (SGLA)
- Fair Value REIT-AG (FVI.F)
- Model Solution Co., Ltd. (417970.KQ)
- Luminescence Technology Corp. (6729.TWO)
- Tongyang Pile Inc (228340.KQ)
- Geninus Inc. (389030.KQ)
- MANHATTAN BRIDGE CAPITAL, INC (LOAN)
- LiveOne, Inc. (LVO)
- YIHO International Co., Ltd. (7590.TWO)
- SITE Centers Corp. (SITC)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.